权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Global Map of Interactions Among Human Cell Surface Proteins and Secreted Ligands

人类细胞表面蛋白和分泌配体之间相互作用的全局图

基本信息

批准号：
10478763
负责人：
Kenan Christopher GARCIA
金额：
$ 171.79万
依托单位：
CALIFORNIA INSTITUTE OF TECHNOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-30 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10478763
关键词：
Address Affect Affinity Chromatography Avidity Award Binding Biochemical Biological Assay Biological Process Biomedical Research Cell Communication Cell Surface Proteins Cell physiology Cell surface Cells Cellular Assay Chimeric Proteins Code Color Communities Development Disease Enzyme-Linked Immunosorbent Assay Evaluation Extracellular Domain Extracellular Protein Funding Gene Expression Genes Goals High-Throughput DNA Sequencing Human Immune system Immunotherapy In Vitro Institution Knowledge Ligands Maps Mass Spectrum Analysis Mediating Methods Nervous system structure Neurons Orphan Peripheral Blood Mononuclear Cell Pharmaceutical Preparations Physiology Process Proteins Research Resources T-Lymphocyte Technology Testing Therapeutic Transmembrane Domain Yeasts anti-tumor immune response base cancer immunotherapy experimental study in vitro Assay in vivo innovation insight knock-down nanoparticle neoplastic cell nerve stem cell new technology new therapeutic target novel therapeutics organ growth programmed cell death ligand 1 programmed cell death protein 1 relating to nervous system screening single cell analysis single cell mRNA sequencing therapeutic target yeast two hybrid system

项目摘要

PROJECT SUMMARY/ABSTRACT The challenge addressed by this proposal is to generate a map, the global human cell-surface interactome, that defines in vitro interactions among the extracellular domains of human cellsurface proteins (CSPs) and secreted proteins. This map will have a major impact on biomedical research, because cell-cell interactions mediated by CSPs are central to human physiology, controlling almost every biological process that is affected by disease. CSPs and secreted ligands comprise the majority of the therapeutic targets that have been successfully developed in recent years. Knowledge of interaction partners is essential for assessing the therapeutic potential of a CSP, since this knowledge defines the biological processes that it controls. For example, PD-1 was identified as a negative regulator of T cell function in 1992, but its value as a target for cancer immunotherapy only became clear much later, when its ligand PD-L1 was identified and found to be expressed on tumor cells. We will not only generate a complete map of in vitro interactions among human CSPs and secreted proteins, but also assess the functions of these interactions in cells of the human immune and nervous systems. This is a huge project, because there are about 2000 human single-transmembrane domain CSPs and 200 “orphan” secreted factors. Creation of a map of pairwise interactions among all of these proteins requires testing 4.8 million interactions. This is beyond the capacity of current screening methods, so execution of this screen at an academic institution will require the development of new technologies. This project is too large to be supported by a traditional RO1, but is perfectly suited to the transformative research award mechanism. Here we propose new ways to multiplex both in vitro biochemical screens and in vivo functional screens, so as to make it possible to define all in vitro interactions among CSPs and secreted ligands and to assess the functions of many of these within a 5-year funding period. To do this, we will first multiplex and sensitize in vitro interactome screens using color-coded beads and high-avidity nanoparticles. We will then develop methods to convert in vitro protein interaction screens into high-throughput DNA sequencing screens, which have a huge multiplexing capacity. For the functional screens, multiplexing single- cell analysis of cell fate perturbations can allow us to assess the effects of many different ligands on single immune system and neural cells in a single experiment. The rationale for the overall approach described here is that it defines a stepwise process in which we systematically develop and optimize screen technologies, then use the technology that performs best for execution of the actual screens.

项目总结/文摘